Protalix BioTherapeutics (PLX) Revenue (2010 - 2026)

Protalix BioTherapeutics has reported Revenue for 17 years, with the latest figure at $19.9 million in Q2 2026.

• On a quarterly basis, Revenue rose 27.07% year-over-year to $19.9 million in Q2 2026; TTM through Jun 2026 was $80.6 million, a 30.14% increase from a year earlier, with the FY2025 full-year figure at $52.7 million, down 1.23% from the prior year.
• Revenue was $19.9 million for Q2 2026 at Protalix BioTherapeutics, down from $33.8 million in the prior quarter.
• The five-year high for Revenue was $35.1 million in Q2 2023, with the low at $3.7 million in Q1 2024.
• Average Revenue over 5 years is $15.2 million, with a median of $13.8 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Revenue soared 300.72% in 2023, then tumbled 61.59% in 2024.
• Over 5 years, Revenue stood at $8.6 million in 2022, then advanced by 21.69% to $10.5 million in 2023, then surged by 73.74% to $18.2 million in 2024, then plunged by 49.93% to $9.1 million in 2025, then surged by 118.11% to $19.9 million in 2026.
• The last three Revenue figures came in at $19.9 million (Q2 2026), $33.8 million (Q1 2026), and $9.1 million (Q4 2025), per Business Quant data.